FDA set to rule Monday on Alzheimer’s drug
WPXI,
On Monday, the U.S. Food and Drug Administration is expected to announce whether a new drug to treat Alzheimer’s disease will…
On Monday, the U.S. Food and Drug Administration is expected to announce whether a new drug to treat Alzheimer’s disease will…
On Monday, the U.S. Food and Drug Administration is expected to announce whether a new drug to treat Alzheimer’s disease will…
On Monday, the U.S. Food and Drug Administration is expected to announce whether a new drug to treat Alzheimer’s disease will…
On Monday, the U.S. Food and Drug Administration is expected to announce whether a new drug to treat Alzheimer’s disease will…
On Monday, the U.S. Food and Drug Administration is expected to announce whether a new drug to treat Alzheimer’s disease will…
While Alzheimer’s disease was first described by Alois Alzheimer in 1906, more than 200 years later, doctors still have no…
Peter Wooding, with his his wife JoAnn, receiving an infusion of the experimental Alzheimer's drug aducanumab in 2017.
Alzheimers disease was first described by Alois Alzheimer in 1906, and now, more than 100 years later, doctors have an…
W hile Alzheimer’s disease was first described by Alois Alzheimer in 1906, more than 200 years later, doctors still have no…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
Dr. William Burke reviewed a PET brain scan at Banner Alzheimer's Institute in Phoenix in 2018.
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease, rather…
Great hopes in Alzheimer's research are currently pinned on the drug aducanumab.
Great hopes in Alzheimer's research are currently pinned on the drug aducanumab.
Great hopes in Alzheimer’s research are currently pinned on the drug aducanumab.
Demenz: Wird Aducanumab bald Alzheimerpatienten helfen? Aducanumab soll das Gedächtnis von Menschen mit Alzheimer stärken.
Biogen has an impressive portfolio of assets that it is continuing to work towards developing.
Der monoklonale Antikörper Aducanumab versprach die erste Therapieoption des Morbus Alzheimers im Frühstadium zu werden.
11:30 22.03.19 – Auch wenn die Hoffnung auf eine wirksame Alzheimer-Therapie in naher Zukunft zerschlagen wurde, sind Experten…
Zwei klinische Studien zur Erprobung eines Alzheimer-Medikaments sind wegen fehlender Aussicht auf Erfolg abgebrochen worden.
It's been notoriously difficult to develop medicines for Alzheimer's disease, the sixth leading cause of death in the United…
Story highlights There are no available treatments for Alzheimer's disease, the sixth leading cause of death in the US…
It's been notoriously difficult to develop medicines for Alzheimer's disease, the sixth leading cause of death in the United…
The latest study of a drug designed to clear amyloid deposits in the brain raises questions about whether focusing on the plaque…
Finding a cure for neurodegenerative diseases such as Alzheimer's is challenging.
Finding a cure for neurodegenerative diseases such as Alzheimer's is challenging.
Finding a cure for neurodegenerative diseases such as Alzheimer’s is challenging.
中国科学院科技战略咨询研究院战略情报研究所研制的“2016全球最受公众关注的科学成果”,通过计量统计遴选出天文学与天体物理[1]、物理学、化学、地球科学、生命科学这五个学科中受到科技界热切关注的科学成果,及中国研究者参与的每个学科TOP30受公众关注的科学成…
中国科学院科技战略咨询研究院战略情报研究所 中国科学院科技战略咨询研究院战略情报研究所研制的“2016全球最受公众关注的科学成果”,通过计量统计遴选出天文学与天体物理[1]、物理学、化学、地球科学、生命科学这五个学科中受到科技界热切关注的科学成果,及中国研究…
Hannover. Das vom US-Pharmakonzern Biogen entwickelte "Aducanumab" zerstört und entfernt Amyloid-Ablagerungen im Gehirn.
A new world of clinical trial data testing is upon us. Older methods to determine a drug's worth are being replaced by more…
Introduction Biogen (NASDAQ: BIIB ) is known primarily for its leading position in treating multiple sclerosis, the most common…
Despite a 99 percent failure rate and a recent setback, Alzheimer’s researchers are plowing ahead with hundreds of experiments …
Photo: Heidi De Marco, HO Alzheimer's advocates say the number of Americans living witht the disease will explode from the…
Despite a 99 percent failure rate and another major setback recently, Alzheimer’s researchers are plowing ahead with hundreds…
Despite a 99 percent failure rate and another major setback recently, Alzheimer's researchers are plowing ahead with hundreds…
Despite a 99 percent failure rate and another major setback recently, Alzheimer’s researchers are plowing ahead with hundreds…
Despite a 99 percent failure rate and another major setback recently, Alzheimer’s researchers are plowing ahead with hundreds…
Despite a 99 per cent failure rate and a recent setback, Alzheimer's researchers are plowing ahead with hundreds of experiments …
By Melissa Bailey, Kaiser Health News Despite a 99 percent failure rate and a recent setback, Alzheimer’s researchers are…
Despite a 99 percent failure rate and a recent setback, Alzheimer’s researchers are plowing ahead with hundreds of experiments …
By Despite a 99 percent failure rate and another major setback last month, Alzheimer’s researchers are plowing ahead with…
Memory loss is a great fear for people as they age, unfortunately, there haven't been many successes at arresting that loss.
Memory loss is a great fear for people as they age, unfortunately, there haven't been many successes at arresting that loss.
Despite a 99 percent failure rate and another major setback last month, Alzheimer’s researchers are plowing ahead with hundreds…
Despite a 99 percent failure rate and another major setback last month, Alzheimer’s researchers are plowing ahead with hundreds…
Despite a 99 percent failure rate and another major setback last month, Alzheimer’s researchers are plowing ahead with hundreds…
R. Scott Turner, Professor of Neurology and Director of the Memory Disorder Center at Georgetown University Hospital, points to…
Dr, a physician at Duke University Health System and coauthor of The Alzheimer's Action Plan, responds to questions sent in…
From the outbreak of Zika virus to advances in Alzheimer's treatment, 2016 has shifted the public debate on health, bringing…
This isn’t about a drug company’s share price. It’s about people’s hopes, fears, and dignity.
Background With diverse revenue streams, Biogen (NASDAQ: BIIB ) is a biotech stock with a certain amount of safety.
Es gibt nur wenige Themen, bei denen sich die politisch sehr unterschiedlichen Kontrahenten Newt Gingrich von den Republikanern…
PLAQUE BUSTER A new Alzheimer’s drug shows early promise in clearing amyloid-beta plaques (illustrated) from the brain.
5. Dezember 2016 Solanezumab, ein vielversprechender Antikörper gegen Beta-Amyloid, enttäuschte bei einer großen randomisierten…
Für den Pharmahersteller ist es ein herber Rückschlag, für die Alzheimer-Forschung eine bittere Pille: Solanezumab, ein Antikörpe…
Illustration by Andy Potts There are not a lot of things that could bring together people as far apart on the US political…
Third quarter 2016 GAAP diluted EPS rise 13%; Non-GAAP diluted EPS rise 16% Nusinersen filed with FDA and EMA for spinal…
] Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including: Total revenues of $3.0 billion, a 6…
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (BIIB) today reported third quarter 2016 financial results, including: Total…
Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including: Total revenues of $3.0 billion, a 6…
Oct 26, 2016 10:59 UTC CAMBRIDGE, Mass.--(Business Wire)--Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016…
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including…
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. ( BIIB ) today reported third quarter 2016 financial results, including: Total…
Biogen Inc. ( NASDAQ: BIIB ) today reported third quarter 2016 financial results, including: Total revenues of $3.0 billion, a 6…
Oct. 26, 2016 10:59 UTC Third quarter 2016 GAAP diluted EPS rise 13%; Non-GAAP diluted EPS rise 16% Nusinersen filed with FDA…
Photo Dale B. Schenk, a scientist and industry leader whose discoveries opened new paths into research on Alzheimer’s disease…